GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
Shares of Infinity Pharmaceuticals took a hit this morning after the company conceded that its mid-stage effort to advance its lead drug duvelisib for rheumatoid arthritis flopped on all three doses that were tried out. Infinity says that it will now scrub the RA program and stay focused on its late-stage deal with AbbVie to move duvelisib through the clinic for blood cancers.
When Alkermes set out to develop ALKS 3831 for schizophrenia, it took a well-known antipsychotic--olanzapine--and combined it with a mu-opioid antagonist called samidorphan with an eye to controlling the disease without spurring the rapid weight gain that has bedeviled patients for years. Today, the company says it got the data it was looking for in Phase II and will now press ahead into a pivotal, late-stage program to see if they can replicate the results on a larger scale.
KB001-A, KaloBios Pharmaceuticals' antibody to treat lung infections in patients with cystic fibrosis, failed a Phase II study and is now joining the scrap heap started after KB003 failed Phase II for severe asthma last year.
Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J's candidate come too late to catch up with its rivals and help combat the current epidemic?
The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.
Shares of Cempra shot up more than 30% in premarket trading on Monday as investors digested news of a promising outcome for its head-to-head study of its lead antibiotic solithromycin.
Shares of Achillion rocketed up Monday morning after the biotech reported that its NS5A drug combined with Gilead's Sovaldi scored a quick cure among a small group of hepatitis C patients after only 6 weeks of treatment.
Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.